Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
Abstract Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbocicl...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13058-019-1149-5 |
| _version_ | 1818606252215762944 |
|---|---|
| author | Lorenzo Rossi Chiara Biagioni Amelia McCartney Ilenia Migliaccio Giuseppe Curigliano Giuseppina Sanna Erica Moretti Alessandro M. Minisini Saverio Cinieri Carlo Tondini Grazia Arpino Antonio Bernardo Angelo Martignetti Emanuela Risi Marta Pestrin Luca Boni Matteo Benelli Laura Biganzoli Angelo Di Leo Luca Malorni |
| author_facet | Lorenzo Rossi Chiara Biagioni Amelia McCartney Ilenia Migliaccio Giuseppe Curigliano Giuseppina Sanna Erica Moretti Alessandro M. Minisini Saverio Cinieri Carlo Tondini Grazia Arpino Antonio Bernardo Angelo Martignetti Emanuela Risi Marta Pestrin Luca Boni Matteo Benelli Laura Biganzoli Angelo Di Leo Luca Malorni |
| author_sort | Lorenzo Rossi |
| collection | DOAJ |
| description | Abstract Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers. |
| first_indexed | 2024-12-16T14:07:54Z |
| format | Article |
| id | doaj.art-7597ce6a4a454fd6a655f6904551e47c |
| institution | Directory Open Access Journal |
| issn | 1465-542X |
| language | English |
| last_indexed | 2024-12-16T14:07:54Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Breast Cancer Research |
| spelling | doaj.art-7597ce6a4a454fd6a655f6904551e47c2022-12-21T22:28:53ZengBMCBreast Cancer Research1465-542X2019-05-012111710.1186/s13058-019-1149-5Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trialLorenzo Rossi0Chiara Biagioni1Amelia McCartney2Ilenia Migliaccio3Giuseppe Curigliano4Giuseppina Sanna5Erica Moretti6Alessandro M. Minisini7Saverio Cinieri8Carlo Tondini9Grazia Arpino10Antonio Bernardo11Angelo Martignetti12Emanuela Risi13Marta Pestrin14Luca Boni15Matteo Benelli16Laura Biganzoli17Angelo Di Leo18Luca Malorni19“Sandro Pitigliani” Medical Oncology Department, Hospital of PratoBioinformatics Unit, Hospital of Prato“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato“Sandro Pitigliani” Translational Research Unit, Hospital of PratoDivision of Early Drug Development, Department of Haematology and Haemato-Oncology, Istituto Europeo di Oncologia, IRCCS, Milano and University of Milano“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato“Sandro Pitigliani” Medical Oncology Department, Hospital of PratoDepartment of Oncology, Azienda Sanitaria Universitaria Integrata di UdineMedical Oncology Department, ASL BrindisiHospital Papa Giovanni XXIIIDepartment of Clinical Medicine and Surgery, University of Naples Federico IIMedical Oncology Department, ICS Maugeri IRCCSOncology Department, Azienda USL Toscana Sud Est, Hospital Alta Val D’Elsa“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato“Sandro Pitigliani” Medical Oncology Department, Hospital of PratoClinical Trial Coordinating Center, AOU Careggi, Istituto Toscano Tumori“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato“Sandro Pitigliani” Medical Oncology Department, Hospital of PratoAbstract Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.http://link.springer.com/article/10.1186/s13058-019-1149-5Metastatic breast cancerCDK4/6 inhibitorsPalbociclibBest sequenceTREnd trial |
| spellingShingle | Lorenzo Rossi Chiara Biagioni Amelia McCartney Ilenia Migliaccio Giuseppe Curigliano Giuseppina Sanna Erica Moretti Alessandro M. Minisini Saverio Cinieri Carlo Tondini Grazia Arpino Antonio Bernardo Angelo Martignetti Emanuela Risi Marta Pestrin Luca Boni Matteo Benelli Laura Biganzoli Angelo Di Leo Luca Malorni Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial Breast Cancer Research Metastatic breast cancer CDK4/6 inhibitors Palbociclib Best sequence TREnd trial |
| title | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial |
| title_full | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial |
| title_fullStr | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial |
| title_full_unstemmed | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial |
| title_short | Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial |
| title_sort | clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and her2 negative metastatic breast cancer enrolled in the trend trial |
| topic | Metastatic breast cancer CDK4/6 inhibitors Palbociclib Best sequence TREnd trial |
| url | http://link.springer.com/article/10.1186/s13058-019-1149-5 |
| work_keys_str_mv | AT lorenzorossi clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT chiarabiagioni clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT ameliamccartney clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT ileniamigliaccio clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT giuseppecurigliano clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT giuseppinasanna clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT ericamoretti clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT alessandromminisini clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT saveriocinieri clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT carlotondini clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT graziaarpino clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT antoniobernardo clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT angelomartignetti clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT emanuelarisi clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT martapestrin clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT lucaboni clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT matteobenelli clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT laurabiganzoli clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT angelodileo clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial AT lucamalorni clinicaloutcomesafterpalbociclibwithorwithoutendocrinetherapyinpostmenopausalwomenwithhormonereceptorpositiveandher2negativemetastaticbreastcancerenrolledinthetrendtrial |